Candel to file BLA for aglatimagene in middle of 2027
Candel Therapeutics reported $203.1M in cash and provided corporate updates on its oncology pipeline and regulatory strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed